The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma
Open accessAbstract
Purpose: To assess the efficacy and toxicity of bortezomib (Velcade; Milennium Pharmaceuticals Inc, Cambridge, MA; formerly PS-341) in patients with metastatic renal cell carcinoma (RCC). Patients and Methods: Thirty-seven patients with metastatic RCC were treated with bortezomib. The first 25 patients enrolled onto the trial were treated with a dose of 1.5 mg/m 2. The dose was decreased to 1.3 mg/m 2 for the subsequent 12 patients, because more than 50% of the patients treated at the higher dose required dose reductions. Bortezomib was given by intravenous administration on a twice-weekly schedule for 2 weeks followed by 1 week without treatment until progression or unacceptable toxicity occurred. Twenty-three patients (62%) previously had undergone nephrectomy, and 19 patients (51%) had previously been treated with cytokine therapy. Results: Of the 37 assessable patients, the best response was a partial response in four patients (11%; 95% CI, 3% to 25%) and stable disease in 14 patients (38%; 95% CI, 23% to 55%). The four patients with partial response experienced response durations of 8, 8+, 15+, and 20+ months. Grade 2 or 3 sensory neuropathy was present in 10 patients (53%) overall. One patient in the 1.5 mg/m 2 group had grade 3 sensory neuropathy; no grade 3 sensory neuropathy was seen in the 1.3 mg/m 2 group. Conclusion: The results of this trial suggest that bortezomib has an antitumor effect in individual patients with metastatic RCC. The small proportion of patients who achieved a partial response does not support routine use in metastatic RCC. Efforts to identify the molecular profile associated with clinical response or combination therapy with interferon alfa or other novel agents, may be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
How Proteolysis Drives the Cell Cycle
King, R. W., Deshaies, R. J., Peters, J.-M., & Kirschner, M. W. (1996) · Science · doi:10.1126/science.274.5293.1652 · Cited by 1,273
Cited by
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & P. Dou, Q. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519752 · Cited by 795
Qiu, B., Ackerman, D., Sanchez, D. J., Li, B., Ochocki, J. D., Grazioli, A., Bobrovnikova-Marjon, E., Diehl, J. A., Keith, B., & Simon, M. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1507 · Cited by 394
“A small phase II clinical trial evaluating Bortezomib mono-therapy for advanced renal cancer revealed partial responses in only 12% (3/25) of ccRCC patients (49).”
Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
Richardson, P. G., Mitsiades, C., Hideshima, T., & Anderson, K. C. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.042905.122625 · Cited by 361
Nuclear Factor-κB in Development, Prevention, and Therapy of Cancer
Van Waes, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2221 · Cited by 292
Dou, Q., & Zonder, J. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140804154511 · Cited by 275
Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat
Cavaletti, G., Gilardini, A., Canta, A., Rigamonti, L., Rodriguez-Menendez, V., Ceresa, C., Marmiroli, P., Bossi, M., Oggioni, N., D'Incalci, M., et al. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.11.010 · Cited by 265
In Vivo Imaging, Tracking, and Targeting of Cancer Stem Cells
Vlashi, E., Kim, K., Lagadec, C., Donna, L. D., McDonald, J. T., Eghbali, M., Sayre, J. W., Stefani, E., McBride, W., & Pajonk, F. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn509 · Cited by 260
THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY
Voorhees, P. M., & Orlowski, R. Z. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141300 · Cited by 247
Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part II
Wilczynski, J., Duechler, M., & Czyz, M. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0132-3 · Cited by 41
Metadata
- Authors
- Kondagunta, G. V., Drucker, B., Schwartz, L., Bacik, J., Marion, S., Russo, P., Mazumdar, M., & Motzer, R. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-09-15
- Volume
- 22
- Issue
- 18
- Pages
- 3720-3725
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2155468968
- Cited by
- 192
- References
- 3
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.